Financials

News Discussions Technicals Forecast Seasonals

PHIL fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. Its products include Nidlegy, Fibromun, Darleukin, Dodekin, Onco IX, Tripokin, OncoFAP, and Dekavil. The company was founded by Dario Neri, Duccio Neri, and Giovanni Neri in 1996 and is headquartered in Siena, Italy.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

PHIL has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company